REG - Arecor Therapeutics - SPECIALTY HOSPITAL FORMULATION COLLABORATION

Arecor TherapeuticsAnnouncement

10/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221110:nRSJ9078Fa&default-theme=true

RNS Number : 9078F  Arecor Therapeutics PLC  10 November 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION

 

Cambridge, UK, 10 November 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that it has signed an exclusive formulation study
collaboration with the pharmaceutical division of one of the world's largest
chemicals marketing and pharmaceuticals companies, which focuses on the
development and commercialisation of speciality drugs.

 

Under the terms of the agreement, Arecor will use its proprietary formulation
technology platform, Arestat™, to develop a differentiated, stable, liquid
drug product, for intravenous administration, that is Ready-to-Use ("RTU").
The new liquid formulation of the product supports safe medication practices
and operational efficiency by eliminating the need for reconstitution.  The
partner will fund the development work and has the option to acquire the
rights to the new proprietary formulation and associated Intellectual Property
under a technology licensing model to further develop and commercialise the
product.

 

This collaboration adds to Arecor's growing portfolio of pre-license
technology partnerships which, subject to licensing, typically include both
potential milestone and royalty payments and could offer significant future
recurring revenue upside potential for the Group.

 

Sarah Howell, Chief Executive Officer of Arecor, said:  "This collaboration
further demonstrates the strength of our proprietary technology platform,
Arestat™, and its potential in the development of Ready-to-Use medicines.
This is a field in which Arecor is building a considerable portfolio of
potential specialty hospital products, as well as bringing our technology and
experience to further our partners' products.  Our expertise in formulating
complex medicines, when combined with our partner's global network and
specific local knowledge of providing access to the major markets worldwide,
will be key to advancing these fast, safe and effective treatments for
patients."

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFLILFLAIIF